QcrC is a potential target for antibody therapy and vaccination to control Campylobacter jejuni infection by suppressing its energy metabolism.

Autor:	Hosomi K; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan., Hatanaka N; Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan.; Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan., Hinenoya A; Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan.; Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan., Adachi J; Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan., Tojima Y; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan., Furuta M; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan., Uchiyama K; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan., Morita M; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan., Nagatake T; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Functional Anatomy, Department of Life Sciences, School of Agriculture, Meiji University, Kawasaki, Japan., Saika A; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore., Kawai S; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan., Yoshii K; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Graduate School of Medicine, Osaka University, Osaka, Japan., Kondo S; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan., Yamasaki S; Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan.; Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan.; Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan., Kunisawa J; Laboratory of Vaccine Materials, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.; Graduate School of Medicine, Osaka University, Osaka, Japan.; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.; Graduate School of Dentistry, Osaka University, Osaka, Japan.; Graduate School of Science, Osaka University, Osaka, Japan.; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.; Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.; Research Organization for Nano and Life Innovation, Waseda University, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Frontiers in microbiology [Front Microbiol] 2024 Jul 02; Vol. 15, pp. 1415893. Date of Electronic Publication: 2024 Jul 02 (Print Publication: 2024).
DOI:	10.3389/fmicb.2024.1415893
Abstrakt:	Introduction: Campylobacter spp. are a public health concern, yet there is still no effective vaccine or medicine available. Methods: Here, we developed a Campylobacter jejuni -specific antibody and found that it targeted a menaquinol cytochrome c reductase complex QcrC. Results: The antibody was specifically reactive to multiple C. jejuni strains including clinical isolates from patients with acute enteritis and was found to inhibit the energy metabolism and growth of C. jejuni . Different culture conditions produced different expression levels of QcrC in C. jejuni , and these levels were closely related not only to the energy metabolism of C. jejuni but also its pathogenicity. Furthermore, immunization of mice with recombinant QcrC induced protective immunity against C. jejuni infection. Discussion: Taken together, our present findings highlight a possible antibody- or vaccination-based strategy to prevent or control Campylobacter infection by targeting the QcrC-mediated metabolic pathway. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Hosomi, Hatanaka, Hinenoya, Adachi, Tojima, Furuta, Uchiyama, Morita, Nagatake, Saika, Kawai, Yoshii, Kondo, Yamasaki and Kunisawa.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu